The expression and the diagnostic value of NOD2 in hepatocellular carcinoma

作者：Jingxin Zhang, Lili Qiao, Ning Liang, Jian Xie, Hui Luo, Guodong Deng · 发表于：Guoji zhongliuxue zazhi · 年份：2016 · DOI：10.3760/cma.j.issn.1673-422x.2016.07.005 · 研究领域：Cancer-related molecular mechanisms research、RNA modifications and cancer、Cancer, Hypoxia, and Metabolism

Objective To investigate the expression of nucleotide-binding oligomerization domain protein 2 (NOD2) in serum of patients with hepatocellular carcinoma (HCC), and to analyse the roles of NOD2 in HCC development and its clinical diagnostic value. Methods This study including 66 patients with HCC in the hospital from March 1, 2013 to December 31, 2014 and 61 healthy controls. Serum NOD2 levels were determined by enzyme-linked immunosorbent assay (ELISA). Analysis of significance was performed with rank sum test using SPSS statistical 16.0 software. Results Serum levels of NOD2 in HCC patients were 171 pg/ml, significantly higher than that of healthy controls(95 pg/ml, Z=-5.00, P=0.00), and the serum NOD2 levels were correlated with clinical stage of HCC (H=56.26, P=0.00). Compared with the serum NOD2 levels in stage Ⅰ, Ⅱ patients (106 pg/ml) and healthy controls (95 pg/ml), the serum NOD2 level in stage Ⅲ and Ⅳ (220 pg/ml) were significantly increased (χ2=31.24, P=0.00; χ2=47.23, P=0.00), but the expression of NOD2 in stage Ⅰ and Ⅱ were nearly equal to that of the healthy controls (χ2=0.36, P=0.83). The ROC analysis revealed that the best diagnostic cutoff-point of serum NOD2 levels for predicting the Ⅲ and Ⅳ stages of HCC was 148.78 pg/ml, meanwhile corresponding sensitivity was 89.1% and specificity was 77.0%. Additionally, correlation analysis demonstrated that there was no significant correlation between NOD2 and alpha-fetal protein (r=0.44, P=0.14). Survival ...